This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Conatumumab
DrugBank Accession Number
DB11646
Background

Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Conatumumab
External IDs
  • AMG 655
  • AMG-655
  • AMG655

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Conatumumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Conatumumab.
AducanumabThe risk or severity of adverse effects can be increased when Conatumumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Conatumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Conatumumab.
AmivantamabThe risk or severity of adverse effects can be increased when Conatumumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Conatumumab is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Conatumumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Conatumumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Conatumumab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
1P48L61KM0
CAS number
896731-82-1

References

General References
Not Available
PubChem Substance
347911222
Wikipedia
Conatumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCarcinoids / Colorectal Cancer / Locally Advanced / Malignant Lymphomas / Metastatic Cancers / Non-Small Cell Lung Carcinoma (NSCLC) / Sarcomas / Solid Tumors / Solid Tumors, Advanced Solid Tumors1
2CompletedTreatmentMetastatic Colorectal Cancer (CRC)1
1CompletedTreatmentDiffuse Large Cell Diffuse Lymphoma / Low Grade Lymphoma / Lymphoma, Hodgkins / Malignant Lymphomas / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentRelapsed Epithelial Ovarian Cancer / Relapsed Fallopian Tube Cancer / Relapsed Primary Peritoneal Cancer1
1, 2CompletedTreatmentAdenocarcinomas of the Pancreas / Malignant Neoplasm of Pancreas / Pancreatic Metastatic Cancer1
1, 2CompletedTreatmentColorectal Cancer / Malignant Neoplasm of Colon / Metastatic Colorectal Cancer (CRC) / Oncology / Rectal Carcinoma1
1, 2CompletedTreatmentColorectal Cancer / Malignant Neoplasm of Colon / Metastatic Colorectal Cancer (CRC) / Rectal Carcinoma1
1, 2CompletedTreatmentLocally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma / Locally Advanced Soft Tissue Sarcoma / Metastatic Soft Tissue Sarcoma / Sarcomas / Soft Tissue Sarcoma (STS) / Unresectable Soft Tissue Sarcoma1
1, 2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2TerminatedTreatmentColorectal Cancer / Locally Advanced / Malignant Neoplasm of Pancreas / Metastatic Cancers / Non-Small Cell Lung Carcinoma (NSCLC) / Ovarian Cancer / Sarcomas / Solid Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at October 20, 2016 20:37 / Updated at February 21, 2021 18:53